Global Endoscopic Retrograde Cholangiopancreatography Market

Endoscopic Retrograde Cholangiopancreatography Market Size, Share, Growth Analysis, By Product type(Endoscopes, Endo-therapy Devices, Imaging Systems, Energy Devices), By Application(Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Duct Stenting), By End user(Hospitals & Clinics, Ambulatory Surgical Centers), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2748 | Region: Global | Published Date: July, 2027
Pages: 219 | Tables: 91 | Figures: 67

Endoscopic Retrograde Cholangiopancreatography Market News

In February 2023, BD made a full-size stride in medical innovation with the introduction of the High-Throughput Single-Cell Multiomics Platform. This cutting-edge platform is designed to significantly increase the scope of clinical discovery by permitting researchers to investigate and recognize unmarried-mobile multi omics records at a high throughput. The introduction of this platform reflects BD's commitment to advancing clinical research and facilitating breakthroughs in numerous fields.

In February 2023, Boston Scientific received approval from the U.S. Food and Drug Administration (FDA) for its LithoVue Elite Single-Use Digital Flexible Ureteroscope System. This FDA approval underscores the machine's compliance with rigorous protection and efficacy standards, positioning it as a reliable and superior scientific tool for urological approaches.

Endoscopic Retrograde Cholangiopancreatography Market Report Snapshots

License Type Top market research company in USA

File Type

$3,500

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Endoscopic Retrograde Cholangiopancreatography Market size was valued at USD 1.9 billion in 2022 and is poised to grow from USD 2.09 billion in 2023 to USD 4.41 billion by 2031, growing at a CAGR of 9.80% in the forecast period (2024-2031).

The competitive environment of the global Endoscopic Retrograde Cholangiopancreatography market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'Olympus Corporation', 'CONMED Corporation', 'HOYA Corporation', 'Fujifilm Holdings Corporation', 'KARL STORZ SE & Co. KG', 'Ambu A/S', 'Johnson & Johnson', 'Boston Scientific Corporation', 'Medtronic PLC', 'Cook Medical', 'B. Braun Melsungen AG.'

ERCP, or endoscopic retrograde cholangiopancreatography, is a specialized clinical system designed for both the identity and treatment of issues affecting the pancreas, liver, gallbladder, and bile ducts. This diagnostic and therapeutic technique integrates luminal endoscopy with fluoroscopy-based imaging, supplying a comprehensive technique to addressing pancreatobiliary illnesses. The technique entails the utilization of an endoscope—a flexible, elongated, and illuminated tube—mixed with X-ray era. The endoscope is carefully guided through the digestive system, bearing in mind direct visualization of the centered organs and systems. Simultaneously, X-ray images are captured to offer distinctive records approximately the pancreas, liver, gallbladder, and bile ducts.

The trajectory of the marketplace is predicted to experience significant propulsion via strategic projects undertaken by means of key enterprise gamers, which includes impactful measures together with product launches, mergers, and acquisitions. A noteworthy instance is the strategic distribution agreement solid between Olympus and EndoClot Plus in April 2022. EndoClot Plus, specializing in hemostasis technology, introduced the EndoClot PHS—a nonthermal, nontraumatic technique designed for rapid and reliable hemostasis in gastrointestinal bleeds. This collaboration is indicative of the marketplace's dedication to advancing current solutions in healing endoscopy.

North America is poised to assert dominance inside the endoscopic retrograde cholangiopancreatography (ERCP) market, driven by using several key factors. The market's expansion in North America is substantially propelled via full-size studies in diagnostic imaging, showcasing a dedication to advancing medical technology and improving diagnostic precision. The rapid introduction of technologically superior ERCP tools, consisting of sphincterotomes, is an indicator of the place's willpower to innovation in healing endoscopy.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Endoscopic Retrograde Cholangiopancreatography Market News

Endoscopic Retrograde Cholangiopancreatography Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Endoscopic Retrograde Cholangiopancreatography Market?

Who are the key vendors in the Endoscopic Retrograde Cholangiopancreatography Market?

What is the key driver of Endoscopic Retrograde Cholangiopancreatography Market?

What is the key market trend for Endoscopic Retrograde Cholangiopancreatography Market?

Which region accounted for the largest share in Endoscopic Retrograde Cholangiopancreatography Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$3,500